Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRegeneron Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 10 | $7.65 | $11.70 | $9.32 |
| Q2 2025 | 5 | $9.32 | $11.75 | $10.45 |
| Q3 2025 | 5 | $10.11 | $12.75 | $11.33 |
| Q4 2025 | 5 | $10.10 | $12.74 | $11.32 |
| Q1 2026 | 4 | $9.92 | $12.51 | $11.12 |
| Q2 2026 | 4 | $10.33 | $13.02 | $11.58 |
| Q3 2026 | 4 | $11.35 | $14.30 | $12.72 |
| Q4 2026 | 4 | $11.53 | $14.54 | $12.93 |
Regeneron Pharmaceuticals, Inc. Earnings Date And Information
Regeneron Pharmaceuticals, Inc. last posted its earnings results on Tuesday, February 4th, 2025. The company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The company had revenue of 3.79 B for the quarter and had revenue of 14.20 B for the year. Regeneron Pharmaceuticals, Inc. has generated $41 earnings per share over the last year ($38.34 diluted earnings per share) and currently has a price-to-earnings ratio of 16.6. Regeneron Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 31st, 2025 based on prior year's report dates.
Regeneron Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/05/2025 | Q4 2024 | N/A | $8.53 | N/A | $3.74 B | $3.79 B |
| 10/31/2024 | Q3 2024 | $11.69 | $12.40 | 0.71 | $3.67 B | $3.72 B |
| 08/01/2024 | Q2 2024 | $10.61 | $13.25 | 2.64 | $3.38 B | $3.55 B |
| 05/02/2024 | Q1 2024 | $10.17 | $6.70 | -3.47 | N/A | $3.15 B |
| 02/05/2024 | Q4 2023 | N/A | $10.88 | N/A | $3.29 B | $3.43 B |
| 11/02/2023 | Q3 2023 | $10.72 | $9.48 | -1.24 | $3.23 B | $3.36 B |
| 08/03/2023 | Q2 2023 | $9.84 | $9.05 | -0.79 | $3.02 B | $3.16 B |
| 05/04/2023 | Q1 2023 | $9.25 | $7.64 | -1.61 | N/A | $3.16 B |
| 02/06/2023 | Q4 2022 | N/A | $11.19 | N/A | N/A | $3.41 B |
| 11/03/2022 | Q3 2022 | $9.48 | $11.66 | 2.18 | $2.92 B | $2.94 B |
| 08/03/2022 | Q2 2022 | $8.53 | $7.47 | -1.06 | $2.79 B | $2.86 B |
| 05/04/2022 | Q1 2022 | $9.74 | $8.61 | -1.13 | N/A | $2.97 B |
| 02/07/2022 | Q4 2021 | N/A | $20.99 | N/A | N/A | $4.95 B |
| 11/04/2021 | Q3 2021 | $10.10 | $15.37 | 5.27 | $2.75 B | $3.45 B |
| 08/05/2021 | Q2 2021 | $17.53 | $29.51 | 11.98 | $3.96 B | $5.14 B |
| 05/06/2021 | Q1 2021 | $9.00 | $10.58 | 1.58 | N/A | $2.53 B |
| 02/08/2021 | Q4 2020 | N/A | $10.90 | N/A | N/A | $2.42 B |
| 11/05/2020 | Q3 2020 | $7.14 | $7.98 | 0.84 | $2.08 B | $2.29 B |
| 08/05/2020 | Q2 2020 | $5.98 | $8.19 | 2.21 | $1.73 B | $1.95 B |
| 05/05/2020 | Q1 2020 | $6.13 | $5.69 | -0.44 | N/A | $1.83 B |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Regeneron Pharmaceuticals, Inc. Earnings: FAQ's
Regeneron Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, January 31st, 2025 based offlast year's report dates.
In the previous quarter, Regeneron Pharmaceuticals, Inc. (:REGN) reported $12.07 earnings per share (EPS) to beat the analysts' consensus estimate of $11.21 by $0.86.
The conference call for Regeneron Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Regeneron Pharmaceuticals, Inc.'s latest earnings report can be read online.
Regeneron Pharmaceuticals, Inc. (:REGN) has a recorded annual revenue of $14.20 B.
Regeneron Pharmaceuticals, Inc. (:REGN) has a recorded net income of $4.41 B.Regeneron Pharmaceuticals, Inc. has generated $40.9 earnings per share over the last four quarters.
Regeneron Pharmaceuticals, Inc. (:REGN) has a price-to-earnings ratio of 16.6 and price/earnings-to-growth ratio is -3.05.